Additional contingent payments would be earned upon reaching various clinical efficacy and product approval milestones in both the US and European Union for up to six products.
With this acquisition, Alexion Pharma has obtains pre-clinical compounds including treatments for patients with ophthalmic diseases such as age-related macular degeneration (AMD), as well as other novel antibody and protein regulators of the complement inflammatory pathways.
Alexion Pharma CEO Leonard Bell said Taligen’s talented scientists and impressive technology will enhance Alexion’s staff and research and development programs, substantially increasing their ability to develop therapies for patients with severe diseases.
"As product development opportunities continue to expand, we look forward to increasing the quality, speed, and throughput of our combined current and future development programs for the benefit of patients worldwide, "Bell said.